Oren Livne

Biography

Oren Livne is a partner in the Transactions Practice Group. He co-chairs the North America Healthcare & Life Sciences Group and serves as a member of the Global Healthcare & Life Sciences Steering Committee. Before beginning his legal career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Practice Focus

Oren Livne counsels clients from startups to multinationals on a variety of corporate and transactional matters globally, including complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, mergers and acquisitions, and other intellectual property focused transactions. His clients include pharmaceutical, biotech, medical device, consumer product, and technology companies.

Representative Legal Matters

Galapagos in the planned creation of a new company with approximately EUR 2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions and amendment of its 10-year global Option, License and Collaboration Agreement with Gilead.
L'Oréal in its partnership with NanoEntek related to technology used in L'Oréal Cell BioPrint, a tabletop hardware device that provides personalized skin analysis.
BMS in its research collaboration and option agreement with AI Proteins for miniprotein-based therapeutics valued up to USD 400 million.
Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
Abbott in its global partnership to connect its continuous glucose monitoring system with Medtronic’s insulin delivery devices.
Astellas in its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.
Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries.
Astellas in its license agreement with 4D Molecular Therapeutics for the use of 4D's proprietary R100 vector for rare ophthalmic targets, including USD 20 million upfront and potential future option fees and milestones of up to USD 942.5 million.
Astellas in its strategic collaboration and option agreement with Cullgen to advance innovative targeted protein degraders, with compensation potentially exceeding USD 1.9 billion if Astellas exercises all of its license options and all milestones for all programs are achieved.
L'Oréal in its strategic partnership with Debut to develop a wide variety of novel ingredients and beauty and personal care products using Debut's proprietary cell-free and biotechnology model.
L'Oréal in its collaboration with Verily to incorporate Verily's stabilization technology into L'Oréal's smart makeup applicator for users with limited hand and arm mobility.
Merck Sharp & Dohme in its collaboration and license agreement with PeptiDream Inc. for the discovery and development of novel peptide drug candidates, including the potential for up to USD 2.1 billion in regulatory, development and commercial milestones.

Professional Honors

Recommended for Transactions, IAM Patent 1000, 2024
LES Deal of Distinction™ Award for Life Sciences in 2023 for the Astellas - Cullgen strategic collaboration and option agreement
Shortlisted for Licensing & Collaboration Attorney of the Year, LMG Life Sciences, 2023, 2024
Leading Life Sciences Lawyer, Licensing & Collaboration, LMG Life Sciences, 2021/22, 2022/23, 2023/24
Rising Star, Super Lawyers New Jersey, 2020-2022
Shortlisted for Innovative Lawyers Award Asia-Pacific, Practice of Law - Healthcare, to Baker McKenzie Healthcare & Life Sciences Group on COVID-19 Response, FT 2021
IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration
Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
Notable Practitioner, IFLR 1000, 2020
Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
Certified Licensing Professional, 2008-2026

Professional Associations and Memberships

New York State Bar Association
New Jersey State Bar Association
Licensing Executives Society

Admissions

New York~United States
New Jersey~United States
U.S. Patent and Trademark Office~United States

Education

New York University (MBA, with distinction) (2012)
New York University School of Law (JD) (2012)
Rutgers University (BS Chemical Engineering, with Highest Honors) (1996)

Languages

English

Panelist, “Navigating the future: Life sciences deal-making amid geopolitical headwinds,” Swiss Biotech Day, May 5, 2025
Co-author, “The U.S. BIOSECURE Act and Its Implications,” Life Science Recht, November 18, 2024
Panelist, "Masterclass: Licensing & Partnering," LSX Investival Showcase, November 2024
Co-author, "The BIOSECURE Act: Potential Implications for Biotechnology Collaborations with Chinese Companies," Baker McKenzie's Global Sanctions and Export Control Blog, June 4, 2024
Moderator, "Creative Structures for Keeping Innovation Alive After the Deal," Bio International Convention, June 2024
Presenter, "Masterclass: Licensing & Partnering," LSX Investival Showcase, November 2023

Panelist, "Diversifying Funding Sources: Founders’ Perspectives," Boston Life Sciences Showcase, September 28, 2023
Moderator and Panelist, "Life Sciences Industry: An update on the global legal landscape," Association of Corporate Counsel, September 13, 2023
Author, "Life sciences licensing from US universities – six areas to consider," ILO Healthcare & Life Sciences Newsletter, January 25, 2023
Presenter, "Masterclass: Moving up the value chain: Out-licensing and collaboration agreement tactics," LSX Investival Showcase, November 2022
Author, "Life Sciences Collaboration and Licence Agreements: Planning for Divorce," ILO Healthcare & Life Sciences Newsletter, January 19, 2022
Presenter, "Masterclass: Partnering & Licensing," LSX Investival Showcase, November 2021
Author, "Perfect Partners: How Pharma and Biotech Can Get the Best Out of Licensing and Collaborations," Intellectual Property Magazine, April 2020
Author, "Secondary Markets for Private Company Shares: Marketplace Overview and Predictive Capability," Glucksman Fellowship Program Student Research Reports, April 2012
Author, "A Cost Conscious Approach to Patent Application Filings," les Nouvelles, Journal of the Licensing Executives Society, Vol. 41, No.2, pp. 115-119, June 2006 (reprinted in 2007 in modified form in Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices)
Author, "Valuing and Monetizing IP Using Existing Organizational Structures," les Nouvelles, Journal of the Licensing Executives Society, Vol. 39, No.1, pp. 9-15, March 2004
Contributor, "Resource Manual for Bioprospecting," Public Interest Intellectual Property Advisors (PIIPA) Web Resource, October 2004 (updated in 2013)
Author, "Investigation of At-Risk Patent Filings," Journal of the Association of University Technology Managers, Vol. 14, pp. 19-29, 2002 (reprinted in the October 2003 issue of Industry and Higher Education)